-transparent.png){kind=logo}
We recently discovered that the ability of cancer patients to generate lymphokine-activated killer (LAK) cells became remarkably augmented after mitomycin C (MMC) administration. Based on our clinical findings, we designed a treatment regimen comprised of MMC 12 mg/m2 given intravenously on day 1 and recombinant interleukin 2 (rIL 2) 700 U/m2 given intravenously every 12 hr from day 4 through day 8, when the generation of LAK cells had been shown to be markedly increased. Ten patients with various advanced carcinomas for which standard therapy had failed or no standard therapy was available, were treated with this regimen. Of these ten, three had a partial response and three others had a minor response. Fevers were common and anemia occurred in four patients, but nevertheless, severe toxicity was not encountered. These results indicated that rIL 2 in combination with MMC might be effective against advanced carcinoma without causing severe toxicity when these drugs are used in an appropriate combination.
T Akiyoshi, and
S Arinaga, and
S Nanbara, and
N Karimine, and
H Inoue, and
K Takamuku, and
R Abe, and
D Watanabe, and
M Nagamatsu, and
H Matsuoka
July 1996,
European journal of cancer (Oxford, England : 1990),
T Akiyoshi, and
S Arinaga, and
S Nanbara, and
N Karimine, and
H Inoue, and
K Takamuku, and
R Abe, and
D Watanabe, and
M Nagamatsu, and
H Matsuoka
January 1999,
Gan to kagaku ryoho. Cancer & chemotherapy,
T Akiyoshi, and
S Arinaga, and
S Nanbara, and
N Karimine, and
H Inoue, and
K Takamuku, and
R Abe, and
D Watanabe, and
M Nagamatsu, and
H Matsuoka
January 1995,
Oncology,
T Akiyoshi, and
S Arinaga, and
S Nanbara, and
N Karimine, and
H Inoue, and
K Takamuku, and
R Abe, and
D Watanabe, and
M Nagamatsu, and
H Matsuoka
April 1983,
Gan to kagaku ryoho. Cancer & chemotherapy,
T Akiyoshi, and
S Arinaga, and
S Nanbara, and
N Karimine, and
H Inoue, and
K Takamuku, and
R Abe, and
D Watanabe, and
M Nagamatsu, and
H Matsuoka
January 1997,
British journal of cancer,
T Akiyoshi, and
S Arinaga, and
S Nanbara, and
N Karimine, and
H Inoue, and
K Takamuku, and
R Abe, and
D Watanabe, and
M Nagamatsu, and
H Matsuoka
July 2017,
Oncotarget,
T Akiyoshi, and
S Arinaga, and
S Nanbara, and
N Karimine, and
H Inoue, and
K Takamuku, and
R Abe, and
D Watanabe, and
M Nagamatsu, and
H Matsuoka
June 1987,
Cancer treatment reports,
T Akiyoshi, and
S Arinaga, and
S Nanbara, and
N Karimine, and
H Inoue, and
K Takamuku, and
R Abe, and
D Watanabe, and
M Nagamatsu, and
H Matsuoka
August 1985,
Tumori,
T Akiyoshi, and
S Arinaga, and
S Nanbara, and
N Karimine, and
H Inoue, and
K Takamuku, and
R Abe, and
D Watanabe, and
M Nagamatsu, and
H Matsuoka
December 1990,
Journal of chemotherapy (Florence, Italy),
T Akiyoshi, and
S Arinaga, and
S Nanbara, and
N Karimine, and
H Inoue, and
K Takamuku, and
R Abe, and
D Watanabe, and
M Nagamatsu, and
H Matsuoka
January 1997,
Journal of immunotherapy (Hagerstown, Md. : 1997),
